Literature DB >> 10677296

Autosomal recessive disorder otospondylomegaepiphyseal dysplasia is associated with loss-of-function mutations in the COL11A2 gene.

M Melkoniemi1, H G Brunner, S Manouvrier, R Hennekam, A Superti-Furga, H Kääriäinen, R M Pauli, T van Essen, M L Warman, J Bonaventure, P Miny, L Ala-Kokko.   

Abstract

Otospondylomegaepiphyseal dysplasia (OSMED) is an autosomal recessive skeletal dysplasia accompanied by severe hearing loss. The phenotype overlaps that of the autosomal dominant disorders-Stickler and Marshall syndromes-but can be distinguished by disproportionately short limbs, severe hearing loss, and lack of ocular involvement. In one family with OSMED, a homozygous Gly-->Arg substitution has been described in COL11A2, which codes for the alpha2 chain of type XI collagen. We report seven further families with OSMED. All affected individuals had a remarkably similar phenotype: profound sensorineural hearing loss, skeletal dysplasia with limb shortening and large epiphyses, cleft palate, an extremely flat face, hypoplasia of the mandible, a short nose with anteverted nares, and a flat nasal bridge. We screened affected individuals for mutations in COL11A2 and found different mutations in each family. Individuals from four families, including three with consanguineous parents, were homozygous for mutations. Individuals from three other families, in whom parents were nonconsanguineous, were compound heterozygous. Of the 10 identified mutations, 9 are predicted to cause premature termination of translation, and 1 is predicted to cause an in-frame deletion. We conclude that the OSMED phenotype is highly homogenous and results from homozygosity or compound heterozygosity for COL11A2 mutations, most of which are predicted to cause complete absence of alpha2(XI) chains.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10677296      PMCID: PMC1288089          DOI: 10.1086/302750

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  26 in total

1.  Conformation sensitive gel electrophoresis for simple and accurate detection of mutations: comparison with denaturing gradient gel electrophoresis and nucleotide sequencing.

Authors:  J Körkkö; S Annunen; T Pihlajamaa; D J Prockop; L Ala-Kokko
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

2.  Stickler syndrome without eye involvement is caused by mutations in COL11A2, the gene encoding the alpha2(XI) chain of type XI collagen.

Authors:  D A Sirko-Osadsa; M A Murray; J A Scott; M A Lavery; M L Warman; N H Robin
Journal:  J Pediatr       Date:  1998-02       Impact factor: 4.406

3.  Oto- spondylo-megaepiphyseal dysplasia (OSMED): clinical description of three patients homozygous for a missense mutation in the COL11A2 gene.

Authors:  M A van Steensel; P Buma; M C de Waal Malefijt; F H van den Hoogen; H G Brunner
Journal:  Am J Med Genet       Date:  1997-06-13

Review 4.  Mutations in fibrillar collagens (types I, II, III, and XI), fibril-associated collagen (type IX), and network-forming collagen (type X) cause a spectrum of diseases of bone, cartilage, and blood vessels.

Authors:  H Kuivaniemi; G Tromp; D J Prockop
Journal:  Hum Mutat       Date:  1997       Impact factor: 4.878

Review 5.  Molecular genetic basis of the human chondrodysplasias.

Authors:  W A Horton
Journal:  Endocrinol Metab Clin North Am       Date:  1996-09       Impact factor: 4.741

Review 6.  The cartilage collagens: a review of their structure, organization, and role in the pathogenesis of experimental arthritis in animals and in human rheumatic disease.

Authors:  M A Cremer; E F Rosloniec; A H Kang
Journal:  J Mol Med (Berl)       Date:  1998-03       Impact factor: 4.599

7.  Conservation of the sizes of 53 introns and over 100 intronic sequences for the binding of common transcription factors in the human and mouse genes for type II procollagen (COL2A1).

Authors:  L Ala-Kokko; A P Kvist; M Metsäranta; K I Kivirikko; B de Crombrugghe; D J Prockop; E Vuorio
Journal:  Biochem J       Date:  1995-06-15       Impact factor: 3.857

8.  Marshall syndrome associated with a splicing defect at the COL11A1 locus.

Authors:  A J Griffith; L K Sprunger; D A Sirko-Osadsa; G E Tiller; M H Meisler; M L Warman
Journal:  Am J Hum Genet       Date:  1998-04       Impact factor: 11.025

9.  Transgenic mice with targeted inactivation of the Col2 alpha 1 gene for collagen II develop a skeleton with membranous and periosteal bone but no endochondral bone.

Authors:  S W Li; D J Prockop; H Helminen; R Fässler; T Lapveteläinen; K Kiraly; A Peltarri; J Arokoski; H Lui; M Arita
Journal:  Genes Dev       Date:  1995-11-15       Impact factor: 11.361

10.  A-2-->G transition at the 3' acceptor splice site of IVS17 characterizes the COL2A1 gene mutation in the original Stickler syndrome kindred.

Authors:  C J Williams; A Ganguly; E Considine; S McCarron; D J Prockop; C Walsh-Vockley; V V Michels
Journal:  Am J Med Genet       Date:  1996-06-14
View more
  26 in total

1.  Adjacent DNA sequences modulate Sox9 transcriptional activation at paired Sox sites in three chondrocyte-specific enhancer elements.

Authors:  Laura C Bridgewater; Marlan D Walker; Gwen C Miller; Trevor A Ellison; L Daniel Holsinger; Jennifer L Potter; Todd L Jackson; Reuben K Chen; Vicki L Winkel; Zhaoping Zhang; Sandra McKinney; Benoit de Crombrugghe
Journal:  Nucleic Acids Res       Date:  2003-03-01       Impact factor: 16.971

2.  The expression patterns of minor fibrillar collagens during development in zebrafish.

Authors:  Ming Fang; Jason S Adams; B Lane McMahan; Raquel J Brown; Julia Thom Oxford
Journal:  Gene Expr Patterns       Date:  2010-07-18       Impact factor: 1.224

3.  A large-scale genetic association study of ossification of the posterior longitudinal ligament of the spine.

Authors:  Taizo Horikoshi; Koichi Maeda; Yoshiharu Kawaguchi; Kazuhiro Chiba; Kanji Mori; Yu Koshizuka; Shigeru Hirabayashi; Kazuhito Sugimori; Morio Matsumoto; Hiroshi Kawaguchi; Makoto Takahashi; Hisashi Inoue; Tomoatsu Kimura; Yoshitaka Matsusue; Itsuro Inoue; Hisatoshi Baba; Kozo Nakamura; Shiro Ikegawa
Journal:  Hum Genet       Date:  2006-04-12       Impact factor: 4.132

Review 4.  Extracellular matrix molecules: potential targets in pharmacotherapy.

Authors:  Hannu Järveläinen; Annele Sainio; Markku Koulu; Thomas N Wight; Risto Penttinen
Journal:  Pharmacol Rev       Date:  2009-06       Impact factor: 25.468

5.  A type II collagen mutation also results in oto-spondylo-megaepiphyseal dysplasia.

Authors:  Yoshinari Miyamoto; Eiji Nakashima; Hisatada Hiraoka; Hirofumi Ohashi; Shiro Ikegawa
Journal:  Hum Genet       Date:  2005-11-15       Impact factor: 4.132

6.  Audiological findings in otospondylomegaepiphyseal dysplasia (OSMED) associated with a novel mutation in COL11A2.

Authors:  Suna Tokgöz-Yılmaz; Sanem Sahlı; Suat Fitoz; Gonca Sennaroğlu; Mustafa Tekin
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2011-01-03       Impact factor: 1.675

7.  Dominant and recessive forms of fibrochondrogenesis resulting from mutations at a second locus, COL11A2.

Authors:  Stuart W Tompson; Eissa Ali Faqeih; Leena Ala-Kokko; Jacqueline T Hecht; Rika Miki; Tara Funari; Vincent A Funari; Lisette Nevarez; Deborah Krakow; Daniel H Cohn
Journal:  Am J Med Genet A       Date:  2012-01-13       Impact factor: 2.802

Review 8.  The triple helix of collagens - an ancient protein structure that enabled animal multicellularity and tissue evolution.

Authors:  Aaron L Fidler; Sergei P Boudko; Antonis Rokas; Billy G Hudson
Journal:  J Cell Sci       Date:  2018-04-09       Impact factor: 5.285

9.  Novel COL11A2 Pathogenic Variants in a Child with Autosomal Recessive Otospondylomegaepiphyseal Dysplasia: A Review of the Literature.

Authors:  Pavalan Selvam; Shekhar Singh; Angita Jain; Herjot Atwal; Paldeep S Atwal
Journal:  J Pediatr Genet       Date:  2019-10-16

10.  A novel retinoic acid-response element requires an enhancer element mediator for transcriptional activation.

Authors:  Laura R Harris; Olli-Pekka Kamarainen; Minna Sevakivi; Gwen C Miller; James W Clarke; Jennifer L Potter; Laura C Bridgewater
Journal:  Biochem J       Date:  2004-10-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.